Rekha Jhunjhunwala is an Indian investor and businesswoman who was recognized for inheriting and managing the vast investment portfolio of her late husband, Rakesh Jhunjhunwala. As per the latest corporate shareholdings filed, Rekha Jhunjhunwala publicly holds 26 stocks with a net worth of over Rs. 38,150.0 crores.
1. Nazara Technologies
Nazara Technologies Limited provides gaming services on a subscription basis, including downloading games and support, as well as e-sports and advertising tech ecosystems. Nazara owns several IPs such as World Cricket Championship, Kiddopia, Animal Jam, and SportsKeeda. Nazara also has offices in Dubai and Singapore.
The company reported a revenue of Rs 535 crores in Q3 FY25, up by 67 percent from its Q3 FY24 revenue of Rs 320 crores. It posted a net profit of Rs 14 crores in Q3 FY25, a decline of 53 percent, against a net profit of Rs 30 crores in Q3 FY24. As of Q4 FY25, Rekha Jhunjhunwala bought a 7.1 percent stake in the company worth Rs 622.6 crore.
2. Geojit Financial Services
Geojit Financial Services Limited, established in 1987 and headquartered in Kochi, India, provides broking and financial services in India, Oman, Kuwait, the UAE, and Saudi Arabia. It is engaged in Financial Services (brokerage, depository, portfolio management) and Software Services (software development and maintenance) segments. It was previously known as Geojit BNP Paribas Financial Services Limited until February 2017.
The company reported a revenue of Rs 172 crores in Q3 FY25, up by 13 percent from its Q3 FY24 revenue of Rs 152 crores. It posted a net profit of Rs 37 crores in Q3 FY25, a decline of 2.6 percent, against a net profit of Rs 38 crores in Q3 FY24. As of Q4 FY25, Rekha Jhunjhunwala bought a 7.2 percent stake in the company worth Rs 154 crore.
Also read: Reliance Industries Revenue Stream: Segment-wise Revenue and Growth Breakdown
3. Wockhardt
Wockhardt Limited, established in 1967 and having its headquarters in Mumbai, India, is a biotech and pharmaceutical company with global operations. It produces infectious disease medicines, including some of them in Phase 3 trials, and markets insulin products, biopharmaceuticals such as Biovac-B and WEPOX, and new drug delivery devices. Wockhardt also offers contract manufacturing and manufactures active pharmaceutical ingredients (APIs).
The company reported a revenue of Rs 721 crores in Q3 FY25, up by 2.85 percent, from its Q3 FY24 revenue of Rs 701 crores. The company turned profitable, reporting a net profit of Rs 20 crores in Q3 FY25, compared to a net loss of Rs 86 crores in Q3 FY24. As of Q4 FY25, Rekha Jhunjhunwala bought a 1.8 percent stake in the company worth Rs 395.3 crore.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
